Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

Cambridge Antibody

Article Abstract:

Cambridge Antibody Technology has undoubted technical abilities, and its Antibody Engine technology performs well, with potential to treat a number of diseases. A number of well-known partners, including American Home Products, have been attracted by the technology, but there is concern that there is no certainty the useful drugs will be developed. The company has services revenues of $4 million annually following an agreement with Wyeth-Ayerst, and further agreements of this kind could allow the company to introduce a new drug without needing a cash call.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1999

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Zeneca

Article Abstract:

David Barnes, chief executive of Zeneca, has denied that the company could be involved in merger talks with SmithKline Beecham. The company has seen a drop in margins due to the cost of new product launches. Zoladex, an anti-cancer preparation, saw a 65% rise in US sales in 1st half 1996. Agrochemicals performed well during this period with a rise in profits of almost a half at 204 million pounds sterling. The company's profit is forecast at 1 billion pounds sterling for the whole of 1996.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1996
Agricultural Chemicals, Pesticide, Fertilizer, and Other Agricultural Chemical Manufacturing, Chemical industry, Zeneca Ltd.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Cambridge Antibody Technology

Article Abstract:

Cambridge Antibody Technology has seen a drop in its stock price and has been affected by a fall in investors confidence. The company may achieve a profit in 2005.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2001
Biochemistry, Research and Development in the Physical, Engineering, and Life Sciences

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Management, Pharmaceutical industry, Drugs, Cambridge Antibody Technology Group PLC
Similar abstracts:
  • Abstracts: A promise of protection. Jupiter Income. Everything themes fine
  • Abstracts: Imperial Tobacco. Impaerial Tobacco
  • Abstracts: Is Something Rotten in Segmentation? My research in marketing: how it happened. There Is No Brand Segmentation
  • Abstracts: Trends, traumas and turning points. Budget day will help the trend. When sell means buy
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.